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I. Introduction
EPIDERMAL growth factor (EGF) is a 53-amino-acid polypeptide (mol wt 6.045 K) that can influ-
ence proliferation and differentiation of a wide variety
of cells (1-6). EGF as well as transforming growth fac-
tor-a (TGF-a), both of which can activate EGF receptor
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(EGF-R), are probably produced locally in many tissues
as local growth factors rather than as systemic hormones.
There is evidence that EGF plays a role in carcinogenesis
and that the EGF-stimulated growth regulatory system
(apart from that of benign cells) is also involved in
proliferation of malignant cells (3). Cellular events are
induced by EGF via its cell membrane receptor (EGF-
R). The EGF-R is a 170 K glycoprotein that can be
divided into an extracellular domain binding EGF or
TGF-a, a short transmembrane domain, and an intra-
cellular domain carrying tyrosine kinase activity (7).
This intracellular domain shows close sequence homol-
ogy with the c-erbB-2 and with neu (8), the rat homolog
of c-erbB-2 oncogene. Increased expression of the EGF-
R gene has been found in a variety of tumors, generally
indicating a more aggressive behavior of cancers com-
pared to those with low or normal expression (9-10)
although this association is not invariant (11). EGF-R
has been identified by several methods including radioli-
gand binding assays, autoradiography, immunocytohis-
tochemistry, immunoenzymatic assays, and measure-
ment of EGF-R transcripts.
EGF can stimulate the growth of normal mammary
epithelium and human breast cancer cells in vitro (12,
13). Receptors for EGF have been demonstrated on sev-
eral breast cancer cell lines, especially on estrogen recep-
tor (ER)-negative tumor cells, and in human primary
tumors and metastases (4,13,14). At present there is no
agreement on the clinical relationships and prognostic
value of EGF-R in human breast cancer. Therefore, the
objective of this review is to examine the clinical associ-
ations reported with EGF-R and breast cancer in a large
series of publications including those from our group.
II. Analytical Review Method
The source of the articles for this review was the
computerized Medline/EBSCO data-base. By such ex-
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tensive review of the literature we selected all papers
reporting relevant data on one or more clinical aspects
of EGF-R in breast cancer. Most studies on prognostic
factors such as EGF-R concern pilot studies (<150 pa-
tients), sometimes followed by more definitive studies by
the same investigators (15). Several groups published
more than one paper on this subject. Comparing the
results of different groups of investigators, for each sep-
arate parameter, we have used the most representative
series of patients reported in the most recent paper from
each group containing the largest series of patients.
Ultimately we found data on EGF-R status in tumors of
5232 patients reported by 40 different groups of investi-
gators. With respect to some clinical relationships we
combined the results of relevant studies, giving more
weight to larger studies, in order to confirm significant
relationships suspected in smaller individual studies.
With respect to the relationship between EGF-R levels
and prognosis as published by nine different groups of
investigators, we have chosen to summarize these results
in descriptive terms in view of the great differences in
their procedural and statistical methods, chosen cut-off
values for EGF-R positivity, and patient characteristics.
III. Results
A. EGF-R measurement and positivity
Several methods for identifying EGF-R in human
breast cancer have been applied including ligand binding
assays (14, 16-54), autoradiography (55-59), immuno-
cytohistochemistry/immunoenzymatic assays (22, 25,39,
43, 60-70), measurement of EGF-R transcripts (71-74),
or EGF-R associated phosphotyrosine kinase activity
(75) (Table 1). At present, there is no agreement on how
best to define EGF-R positivity. Apart from different
techniques, different cut-off levels have been used re-
sulting in a wide variety of reported EGF-R positivity
incidence ranging from 14-91% (Table 1). With Scat-
chard analysis the reported dissociation constant (Ka)
values varied from 0.2-4.6 nM. Some authors (25, 51, 54)
report a good correlation between Scatchard analysis and
single saturation dose ("two-point") assays. With respect
to tumor EGF-R content, median values were reported
between 1.1 and 40 fmol/mg membrane protein, while
levels of individual tumors ranged from 0-3600 fmol/mg
protein (Table 1). In fact, while significant specific bind-
ing of EGF (41) and phosphotyrosine kinase activity (75)
was shown in 91% of tumors, a high level of EGF-R
determined by Scatchard analysis was present in only
about a third of all tumors (41). EGF-R gene amplifica-
tion is rare, occurring in 0-14% of breast cancers (71, 76,
77); however, EGF-R transcripts are demonstrable in
46-51% of primary tumors (71-74).
In 2500 (48%) of 5232 tumors investigated by 40 dif-
ferent study groups, EGF-R status was assessed as pos-
itive (Table 2). This percentage of 48% does not clearly
differ from the mean (45%) of the EGF-R positivities
reported by these individual study groups (Table 2).
When comparing the results of different techniques it is
striking to note that the average EGF-R positivity
showed less difference between the respective techniques
used, varying from 42% for immunological methods to
45%, 46%, and 48% for the radioligand binding assay,
autoradiography, and measurement of EGF-R tran-
scripts, respectively (Table 2). Only the single study
detecting EGF-R associated kinase activity showed 91%
positivity. There appears to be a close correlation be-
tween biochemical and immunological methods of detec-
tion of EGF-R (22, 25, 36, 43, 64). Grimaux et al. (64)
and Koenders et al. (53) demonstrated no difference in
results after either short- or long-term storage of tumors
or membranes, respectively.
B. Relationship with other prognostic factors
1. Relationship with steroid receptor status. In contrast
to two initial studies (14,16) showing only a tendency to
a negative relationship and one immunohistochemical
study (66) of EGF-R, at least 28 different groups have
reported a negative relationship between EGF-R and
ER levels irrespective of the measuring technique used
(Table 3). Interestingly, this was true despite great
differences in reported ER-positive rates ranging from
34-82%. In general, EGF-R positivity was observed in
29-91% (mean: 59%) of ER-negative and in 4-51%
(mean: 29%) of ER-positive tumors reported by 21 dif-
ferent laboratories (14, 21, 26, 35, 37-39, 41, 43, 44, 47,
48, 50, 52-54, 61, 64, 66, 67, 71).
With respect to the progesterone receptor (PR), most
groups (12 of 19) have reported a negative relationship
between EGF-R and PR levels (Table 3). In PR-negative
tumors EGF-R positivity ranged from 23-91% (mean
51%) and in PR-positive tumors from 6-55% (mean 32%)
(14, 35, 37-39, 41, 50, 53, 64, 66, 67, 71). In summary,
mean EGF-R positivity is twice as high in ER or PR-
negative tumors (59-51%) as compared to ER or PR-
positive tumors (29-32%).
With respect to the ER-regulated proteins ER-D5 and
P24, Home et al. (78) failed to demonstrate any signifi-
cant relationship between these proteins and either EGF-
R or ER status.
Finally, although an association between EGF-R and
total protein kinase C determined by phorbol-ester bind-
ing was not observed, Wyss et al. (31) demonstrated a
negative relationship between total protein kinase C
levels and steroid receptor levels in human primary
breast cancer.
2. Relationship with age or menopausal status. Nine
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groups of investigators have studied the relationship
between age and tumor EGF-R levels. Seven groups (14,
33, 35, 39, 41, 44, 54, 64) found no correlation between
age and EGF-R, while two groups (31, 47) reported a
negative relationship. Grimaux et al. (39, 64) made sim-
ilar observations for both the biochemical and immuno-
logical EGF-R assays. With respect to menopausal sta-
tus, Sainsbury et al. (24) reported 45% and 30% EGF-R
positivity in premenopausal and postmenopausal pa-
tients, respectively. Six other groups found no relation-
ship between menopausal status and EGF-R levels (20,
35, 39, 41, 44, 66).
TABLE 1. EGF-R positivity in primary breast cancers measured by radioligand binding assay (RBA), autoradiography (AUT), immunocytochem-
istry or immunohistochemistry (IH), immunoenzymetric assay (IEMA), EGF-R transcripts (mRNA), and EGF-R associated phosphotyrosine
kinase activity (PKA)
First author
A
1. Fitzpatrick
2. Peyrat
3. a. Perez
b. Skoog
c. Macias
d. Rios
4. a. Sainsbury
b. Sainsbury
c. Sainsbury
d. Harris
e. Nicholson
f. Sainsbury
g. Nicholson
5. Wyss
6. Pekonen
7. a. Delarue
b. Spyratos
8. a. Battaglia
b. Battaglia
9. Cappelletti
10. Grimaux
11. a. Foekens
b. Foekens
12. Fekete
13. a. Toi
b.Toi
14. Bauknegt
15. Zeillinger
16. Costa
17. Barker
18. Llorens
19. Bolla
20. Etienne
21. Lefebvre
22. Koenders
23. Bolufer
p
D
24. a. Spitzer
b. Spitzer
25. a. Reubi
b. Reubi
Ref.
(14)
(16)
(17)
(18)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(30)
(31)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
(40)
(41)
(42)
(43)
(44)
(45)
(46)
(47)
(48)
(49)
(50)
(51)
(52)
(53)
(54)
(55)
(56)
(57)
(58)
Year
1984
1984
1984
1986
1987
1988
1985
1985
1987
1988
1988
1988
1990
1987
1988
1988
1990
1988
1988
1988
1989
1989
1989
1989
1989
1990
1989
1989
1989
1989
1989
1990
1990
1990
1991
1990
1987
1988
1988
1989
n
137
65
95
37
72
225
104
108
135
228
246
264
231
238
171
100
109
55
89
136
68
44
214
335
50
91
59
50
68
44
67
177
120
55
531
220
24
50
35
36
Method
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
AUT
AUT
AUT
AUT
Kd(nM)
2.0
1.0
1.84
2.0
0.7-2.3
0.17-2.9
2.0
1-3
3.9
4.6
2.0
0.55
0.2
0.32
0.3
0.67
1.3
0.6
0.5
2.5
EGF-R content (fmol/mg)e
Mean
8.4
17.3
47
47
6
74
8.3
Median
3.2
11.0
5.5
4.0
1.1
3.7
27
4
13
1.3
10
40
8.9
Range
tumors
0-121
0-64
0-80°
0-120°
0-43
0-47
0-187
0-173
0-210
0-55
0-25
0-275
0-33
0-215
0-317
0-35
0-57
0-50
0-1448
3-3600
0-216
Cut-off
(fmol/mg)
1
S.B > 1%"
1
10°
10°
1
4
4 or S.B/
T>75%
10
10
10
10
10
1.4
S.B>2%
5-10
10
1.5
1.5
30
45
5
Signif S.B.
Signif S.B.
1
1
1
1
10
10
3
3
5
"Non-occupied"
"Total" EGF-R
3
0.5e
1.2*
1.0*
Positive
(%)
48
48
42
27
27
43
32
42
35
35
32
33
35
54
±15
(7-26)
22
34
42
57
46
32
37
(70)
91
67
36
43
33
16
16
34
36
25
79
47
76
57
42
66
64
29
28
continued
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TABLE 1. Continued
First author
C
26. a. Sainsbury
b. Harris
27. Walker
28. Wrba
29. Betta
30. Toi
31. Moller
32. Grimaux
33. a. Gasparini
b. Bevilacqua
34. Lewis
35. Tsutsumi
36. Kommoss
37. Hainsworth
D
38. Guerin
39. Coombes
E
40. Baugnet-Mahieu
Ref.
(22)
(25)
(60)
(61)
(62)
(43)
(63)
(64)
(65)
(66)
(67)
(68)
(69)
(70)
(71)
(73)
(75)
Year
1985
1988
1986
1988
1989
1989
1989
1990
1990
1990
1990
1990
1990
1991
1989
1990
1990
n
48
48
88
54
50
197
220-280
86
134
90
36
55
71
221
107
134
Method
I.H.
I.H.
I.H.
I.H.
I.H.
I.H.
I.H.
IEMA
I.H.
I.H.
I.H.
I.H.
I.H.
I.H.
EGF-R mRNA
EGF-R-mRNA
EGF-R PKA
MoAb
EGF-Rl
EGF-Rl
EGF-Rl
EGF-Rl
EGF-Rl
EGF-Rl
EGF-Rl
EGF-Rl
EGF-R528
EGF-Rl
EGF-Rl
EGF-Rl
EGF-Rl
Mean Median Range
(fmol/mge or score of
staining)
0-3+
0-3+
0-3+
0-3+
0-3+
0-2+
0-2+
18 13 0-100
0-2+
0-3+
0-4+
Cut-off Positive
/ f* 1 / \ . / fff \
(fmol/mg) tumors (%)
Correlated
with RBA
48
>2+ 42
>1+ 60
65
>1+ 34
>1+ 34
>20 fmol/mg 33 correlated
with RBA
60
2:1+ 51
>2+ 14
50
60
17
46
51
91
0
 Atomoles//ig DNA.
6
 Femtomoles/mg tissue protein.
c
 Femtomoles/mg homogenate.
d
 S.B., Specific binding.
e
 Femtomoles/mg membrane protein.
3. Relationship with tumor size. Fourteen groups (20-21,
33, 35, 39, 41, 44, 47, 50, 54, 61, 62, 66, 67, 70) have found
no significant correlation between tumor size and EGF-
R levels. On the other hand, Sainsbury and associates
(24) and Harris and Nicholson (25) reported a significant
positive correlation between EGF-R and increasing tu-
mor size. In addition, Spitzer et al. (56) found higher
EGF-R levels in larger tumors (>4 cm). In contrast,
Cappelletti et al. (38) observed that tumors larger than 3
cm were mostly EGF-R-negative, while smaller tumors
(<3 cm) were almost equally distributed among the EGF-
R-positive and -negative subsets. Bolla et al. (50) and
our group (41) found a tendency to higher EGF-R levels
in Tl tumors when compared to T2 and T3 tumors,
respectively. Thus only two (25, 56) of 17 study groups
found a positive correlation between tumor size and
EGF-R levels, while three others (38, 41, 50) found a
trend toward a negative relationship.
4. Relationship with lymph node status and recurrences.
Reports on the relationship between EGF-R and lymph
node status are contradictory. EGF-R relationship to
nodal status can be expressed in different ways, i.e. 1)
EGF-R positivity or levels in primary tumors correlated
with number of lymph nodes involved by metastases, or
2) EGF-R positivity or levels measured in lymph node
metastases compared with those measured in the primary
tumors.
Sainsbury et al. (24) observed that EGF-R positivity
in primary tumors is higher in patients with nodal in-
volvement (N+) as compared to node-negative (N-)
patients (55% vs. 30%). Battaglia etal. (37) also reported
a higher incidence in N+ patients {11.1%) than in N—
patients (25.7%). In addition, Bolufer et al. (54) found
that nodal involvement correlated significantly with
EGF-R status only in the ER+ tumor subgroup, but not
in all tumors. In noninflammatory breast cancer Guerin
et al. (71) found that the presence of EGF-R transcripts
increased linearly with the number of positive lymph
nodes. Hainsworth et al (70) also found that EGF-R
expression correlated with the number of involved lymph
nodes. However, 15 groups found no significant correla-
tion between EGF-R positivity in the primary tumor and
the presence or number of axillary lymph node metas-
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TABLE 2. Mean EGF-R positivity by method in 40 different series of
patients
Method
RBA
Autoradiography
Immunologically
EGF-R transcripts
EGF-R associated
kinase activity
Total
No. of series
(n)
23
2
12
2
1
40
A.
n
3533
86
1151
328
134
5232
Patients
EGF-R+
1723 (49%)
42 (49%)
451 (39%)
162 (49%)
122 (91%)
2500 (48%)
B. EGF-R
positivity (%)
Mean Range
45 (15-91)
46 (28-64)
42 (14-65)
48.5 (46-51)
91
45% (14-91)
Part A, Mean EGF-R positivity based on all individual patients
included, giving more importance to larger series of patients than to
smaller series.
Part B, Mean and range of EGF-R positivity based on the reported
percentages for each separate series (irrespective the size of the series).
tases (16, 21, 33, 35, 39, 41, 44, 47, 50, 54, 56, 61, 62, 66,
67). Grimaux et al. (39), however, reported that EGF-R
was often elevated in the tumors of patients with less
than four involved nodes, while Toi et al. (43) observed
a positive correlation between EGF-R status and lym-
phatic vessel invasion. Spitzer et al. (56) observed higher
EGF-R levels in the primary tumors of patients with
lymph node metastases than in those primary tumors
that lacked lymph node metastases (8.1 us. 3.4 fmol/mg,
respectively), but this difference was not significant (P
<0.1).
With respect to EGF-R positivity and EGF-R levels
in lymph node metastases or recurrences vs. those in the
primary tumors, Sainsbury et al. (22) reported 71% pos-
itivity in the lymph node metastases vs. 32% in the
primary tumors. Macias et al. (19) also reported a signif-
icantly higher incidence of EGF-R positivity in lymph
node metastases (52%) or recurrences (47%) than in
primary tumors (25-7%). Battaglia et al (37) observed a
median increase in EGF-R levels of 157% (range 27-
590%) in lymph node metastases; overall, EGF-R levels
were significantly (P < 0.05) higher in metastases than
in primary tumors (median: 3.7 vs. 2.2 fmol/mg protein).
Grimaux et al. (39) also found higher mean EGF-R levels
in tumor-bearing nodes as compared to primary tumors
(10.37 us. 6.03 fmol/mg protein), but this difference did
not appear to be statistically significant. These authors
did observe a significant correlation between EGF-R
levels in the nodes and primary tumors of 10 patients
investigated.
In conclusion, nine (19, 24, 37, 39, 43, 54, 56, 70, 71)
of 20 studies showed a positive relationship between
EGF-R and lymph node status, but in only five (19, 24,
36, 70, 71) of these was this relationship statistically
significant.
5. Relationship with histology. Fitzpatrick et al. (14) re-
ported that [125I]EGF binding approached a significant
correlation with the percentage of malignant breast cells.
Using immunohistochemistry Moller et al. (63) showed
EGF-R expression in ductal, lobular, and myoepithelial
cells, but only occasionally in stroma cells. In addition,
Battaglia et al. (37) reported that the stroma was com-
pletely unreactive to monoclonal antibodies against
EGF-R, while only malignant cells stained positive. Us-
ing autoradiography Spitzer et al. (55) also observed that
fat and connective tissues were almost devoid of any
EGF binding. On the other hand, Tsutsumi et al. (68)
found that in a few carcinomas EGF-R positivity local-
ized only to stromal cells. EGF-R levels may be de-
creased, increased, or unchanged in cancer cells as com-
pared with their normal counterpart (3). Pekonen et al.
(33) reported no difference in EGF-R binding in normal
tissue from that found in cancer tissue, and the only
normal tissue with high EGF binding was adjacent to a
carcinoma.
Generally speaking, there seems to be no clear rela-
tionship between EGF-R and histological type of breast
cancer (Table 4). A higher EGF-R positivity was found
in ductal carcinomas as compared to lobular carcinomas
by Skoog et al. (18) (36% vs. 0%), Sainsbury et al. (27)
(34% vs. 21%), and Costa et al. (47) (23% vs. 6%), while
Wrba et al. (61) (58% vs. 57%), Toi et al. (44) (43% vs.
33%), and Grimaux et al (64) (31% vs. 42%) found no
significant difference in EGF-R positivity between ductal
and lobular carcinomas, respectively. Spitzer et al. (55)
also found no significant difference in EGF-R levels
between ductal and lobular carcinomas (9.7 versus 7.4
fmol/mg). EGF-R has been demonstrated in most sub-
types of primary breast cancer (18, 27, 61, 64), although
positivity of EGF-R seems somewhat lower in mucoid
and tubular tumors (20%), which appears in agreement
with the reported better long-term survival attributed to
these well differentiated tumor types (79). As summa-
rized in Table 4, EGF-R-positivity was frequently found
in medullary carcinomas (88%), but Moller et al. (63),
using immunohistochemistry, reported finding EGF-R
in only one of seven patients with medullary breast
tumors. EGF binding correlated with number of mitoses
(55, 56) especially in node-positive patients (56), and
EGF-R transcripts were more frequently detected in
inflammatory breast cancer (58%) than in noninflam-
matory breast cancer (39%) (71). It is interesting to note
that Reubi and Torhorst (57) reported high EGF-R den-
sity in necrotic tumor areas.
6. Relationship with tumor differentiation and grade. Sev-
enteen groups studied the relationship between EGF-R
and tumor differentiation and grade. Ten different
groups (23-25, 33, 34, 39, 44, 50, 54, 56, 63, 64, 70)
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TABLE 3. Relationship between steroid receptors (ER, PR) and EGF-R
First author Ref. Method for RelationEGF-R with ER
% of EGFR+
ER-vs ER+
Cut-off for
ER (fmol/
mg)
ER+ Tumors Relation
(%) with PR
%ofEGFR+
PR-vs PR+
Cut-off for
PR (fmol/
mg)
PR+
tumors
1. Fitzpatrick
2. Peyrat
3. a. Perez
b. Skoog
c. Macias
d. Rios
4. a. Sainsbury
b. Sainsbury
c. Sainsbury
d. Harris
e. Nicholson
5. Wyss
6. Pekonen
7. a. Delarue
b. Spyratos
8. a. Battaglia
b. Battaglia
9. Cappelletti
10. Grimaux
11. a. Foekens
b. Foekens
12. Fekete
13. a. Toi
b. Toi
14. Costa
15. Barker
16. Llorens
17. Bolla
18. Etienne
19. Lefebvre
20. Koenders
21. Bolufer
22. Wrba
23. Betta
24. Toi
25. Grimaux
26. Bevilacqua
27. Lewis
28. Hainsworth
29. Guerin
30. Coombes
31. Baugnet-Mahieu
(14)
(16)
(17)
(18)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(31)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
(40)
(41)
(42)
(43)
(44)
(47)
(48)
(49)
(50)
(51)
(52)
(53)
(54)
(61)
(62)
(43)
(64)
(66)
(67)
(70)
(71)
(74)
(75)
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
RBA
IH
IH
IH
IH
IH
IH
IH
mRNA
mRNA
PKA
NS
NS
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
NS
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
NS
Neg
Neg
Neg
Neg
Neg
Neg
NS
Neg
Neg
Neg
Neg
Neg
41 us. 40
51 vs. 33
39 vs. 22
54 vs. 29
61 vs. 8
71 vs. 6
61 vs. 6
52 vs. 12
53 us. 13
50 vs. 13
52 vs. 22
58 vs. 33
68 vs. 42
73 vs. 35
58 vs. 20*
59 vs. 26
91 vs. 47
63 vs. 24
72 vs. 24
29 vs. 5
57 vs. 17
45 vs. 19
65 vs. 37
75 vs. IT
85 vs. 46
48 vs. 31
77 vs. 51
69 vs. 18
55 vs. 25
50 vs. 51
32 vs. 4
61 vs. 33
50
10
10
0.4°
0.1-0.3°
10
5
5
5
5
5
10
10
10
10
10
10
10
10
10
10
5
5
20
5
10
10
10
10
Erica 1-3*
Erica > 10%6
10
Erica > 5%
10
51
50
68
45
51
43
46
76
76
61
65
40
70
68
50
78
82
67
60
54
52
51
77
72
34
65
68
80
73
64
62
NS
NS
Neg
Neg
Neg
Neg
Neg
Neg
Neg
NS
Neg
Neg
Neg
NS
Neg
Neg
Neg
Neg
NS
NS
Neg
NS
43 vs. 38
37 vs. 11
43 vs. 19
61 vs. 22
68 vs. 24
65 vs. 37
49 vs. 23
41 vs. 32
91 vs. 47
34 vs. 19
72 vs. 49
41 vs. 27
46 vs. 55
23 vs. 6
50 vs. 35
50
10
10
10
10
20
10
25
10
10
10
10
10
10
10
10
Prica > 5%b
10
65
61
39
49
24
63
50
50
56
68
62
65
73
51
54
46
See Table 1 for patient number, EGF-R cut-off levels and EGF-R positivity.
RBA, Radioligand binding assay; IH, immunocytohistochemistry; mRNA, EGF-R transcripts; PKA, EGF-R associated phosphotyrosine kinase
activity; NS, not significant.
a
 Atomoles/Vg DNA.
* Other cut-off levels for EGF-R (see Table 1).
c
 "Total" EGF-R.
demonstrated a positive relationship between EGF-R
and grade, poorly differentiated tumors showing a higher
percentage of EGF-R positivity and higher EGF-R levels.
In contrast, eight groups (16, 35, 41, 60-62, 66, 67) did
not find a significant correlation between these two
parameters. Bolufer et al (54) found a positive relation-
ship within the ER-negative, but not the ER-positive
subgroup.
7. Relationship with tumor ploidy. Seven groups (20, 35,
39, 47, 60, 64, 65) studied the relationship between EGF-
R and tumor ploidy, also known as the tumor DNA-
index or content as determined by flow cytometry. Only
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TABLE 4. The EGF-R in different histological subtypes of mammary tumors
Type
Ductal invasive
Ductal in situ
comedo-type
Lobular invasive
Lobular in situ
Mucoid/Colloid
Apocrine
Clear cell
Medullary
Tubular
Papillary
Carcinoid
Cystosarcoma
Fibrosarcoma
Fibroadenomas
Total:
Skoog(18)
8/22 (36%)
0/9 (0%)
0/4
2/2
0/3
Sainsbury (27)
81/239 (34%)
3/14 (21%)
1/3
o/i
0/3
o/i
1/2
o/i
Costa (47)
10/44 (23%)
1/18 (6%)
Wrba (61)
31/53 (58%)
2/3
3/4
8/14 (57%)
2/3
4/5
2/4
0/1
Toi (44)
34/80 (43%)
2/4
2/6 (33%)
1/1
Grimaux (64)
69/220 (31%)
7/17 (41%)
10/24 (42%)
1/2
2/10 (20%)
1/2
1/1
0/3
1/1
1/1
2/2
Overall
233/658 (35%)
11/24 (46%)
3/4
24/85 (28%)
2/3
5/20 (20%)
1/2
o/i
7/8 (88%)
2/10 (20%)
1/1
o/i
2/3
0/2
2/5
293/831 (35%)
N.B. Spitzer et al. (55): mean EGF-R ductal ca (n = 16) = 9.7 fmol/mg
mean EGF-R lobular ca (n = 18) = 7.4 fmol/mg
Walker and Camplejohn (60) found a significant corre-
lation between these two parameters while six groups did
not find any significant relationship (Table 5). All series
showed a higher incidence of EGF-R positivity in aneu-
ploid tumors (mean 36%; range 21-50%) than in diploid
tumors (mean 13%; range 0-29%). Taking the absolute
numbers reported in five studies together (Table 5), we
calculated the presence of EGF-R positivity in 88 of 253
aneuploid tumors (35%) vs. only 17 of 114 diploid tumors
(15%) [P < 0.0001, method of Der Simonian and Laird
(79a), 1986]. Thus, most investigators did not find any
significant correlation between EGF-R and DNA-index
probably due to the small number of patients in their
series of patients, but the overall incidence of EGF-R
may be 2 to 3 times higher in aneuploid than in diploid
tumors.
8. Relationship with parameters for cellular proliferation.
Nine groups studied the relationship of EGF-R with
thymidine labeling index (n = 1), S-phase fraction (n =
3), Ki-67 index (n = 4), or mitotic activity (n = 1).
Macias et al. (20) found EGF-R positivity in 33% of 39
tumors with a high (>5%) labeling index vs. 13% of 16
tumors with a low (<5%) index, but this difference was
not statistically significant. Walker and Camplejohn (60)
demonstrated a close correlation (P < 0.01) between the
presence of EGF-R and high (>14%) S-phase content in
48 tumors investigated, but Costa et al. (47) and Grimaux
et al. (64) did not find a significant correlation in series
of 28 and 60 tumors, respectively. With respect to Ki-67
immunoreactivity, Toi et al. (44) found that in 27 tumors
the average proportion of Ki-67-stained cells in EGF-R-
positive tumors was 25.4% in contrast to 8.6% in EGF-
R-negative ones (P < 0.01). Three other groups (61, 62,
66) were not able to demonstrate a significant correlation
between these two parameters in series of 88, 54, and
134 patients, respectively. Finally, Spitzer et al. (55, 56)
reported a significant positive correlation between the
number of mitoses counted under light microscopy and
EGF binding, but this association was mainly in N+
patients (56). In sum, only three (44, 55, 60) of the nine
studies reported any correlation between EGF-R and
parameters relating to high cellular proliferation, but
these series were all relatively small.
9. Relationship with oncogenes. Although EGF-R is struc-
turally homologous to the c-erhB-2/neu oncogene (8)
and both appear to be negatively correlated with steroid
receptor status, there is no agreement on a (potential)
positive association between EGF-R and c-erbB-2/HER-
2/neu. Hainsworth et al. (70) and Marx et al. (80) did
find a positive correlation between expression of EGF-R
and c-erbB-2, but other reports (30, 46, 81, 82) indicate
the opposite or no relationship. Tsutsumi et al. (68)
observed a single case of breast cancer that overexpressed
both EGF-R and neu in reciprocal immunohistochemical
staining patterns, indicating that EGF-R positive cells
were also not overexpressing the neu protein. Zeillinger
et al. (46) investigated the relationship between HER-2
amplification, steroid receptors, and EGF-R in 291 pri-
mary breast cancers. HER-2 gene amplification was dem-
onstrated in 18% of the tumors, in 14% of ER-positive
and in 28% of ER-negative tumors. In this large series
no association between HER-2 amplification and either
EGF-R or androgen receptor was observed.
Hainsworth et al. (70) showed that EGF-R membrane
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TABLE 5. Relationship between EGF-R status and DNA pattern
Authors (Ref.)
1. Macias (20)
2. Walker (60)
3. Spyratos (35)
4. Grimaux (RBA) (39)
5. Grimaux (IEMA) (64)
6. Costa (47)
7. Gasparini (65)
Total
Absolute numbers EGF-R+
Aneuploid vs. diploid
15/46 us. 3/24
19/38 vs. 1/10
29/78 vs. 9/31
14/38 vs. 0/16
11/53 vs. 4/33
88/253 (35%) vs. 17/114 (15%)
% EGF-R+
Aneuploid vs. diploid
33 vs. 13
50 us. 10
37 vs. 29
37 vs. 0
21 vs. 12
x = 36% us. 13%
P
NS
P < 0.05
NS
NS
NS
NS
P = 0.08
P < 0.0001°
;
° Method of Der Simonian and Laird (79a).
staining was a much stronger prognostic indicator than
c-erbB-2 product or ras p21 staining; in contrast, Wright
et al. (82), applying multivariate analysis, demonstrated
that both lymph node status and c-erbB-2 oncoprotein
staining were more important prognosticators than EGF-
R as measured by ligand binding assay.
Nicholson et al. (30) reported that patient prognosis
based on neu was independent of EGF-R status and that
the combination of neu positivity with EGF-R increased
the prognostic power, showing an apparently additive
effect in predicting a more aggressive course of disease.
This is in agreement with recent experimental data show-
ing that combinations of moderate levels of expression
of EGF receptors and c-erbB-2, which are not individ-
ually capable of cell transformation, can together produce
fully transformed cells (83, 84).
EGF-R was barely detectable in ras transfected cells,
while myc transfected cells were much more sensitive to
the growth-stimulatory effects of EGF without an in-
crease in EGF-R levels as compared to nontransfected
cells (6, 25).
10. Relationship with other growth factor or peptide hor-
mone receptors. In agreement with the results of Pekonen
et al. (33) we did not find an association between EGF-
R and insulin-like growth factor I receptor levels (41).
In addition, Peyrat et al. (16) and Fekete et al. (42)
demonstrated no relationship with tumor PRL-R con-
centrations and [D-Trp6]-LHRH binding sites, respec-
tively.
Reubi et al. (59) discussed an inverse relationship
between the presence of somatostatin receptors (SS-R)
and EGF-R measured by autoradiography. They dem-
onstrated the presence of EGF-R in only 18 of 71 (25%)
SS-R-positive primary breast cancers (57,58). The tissue
location of SS-R did not coincide with that of EGF-R
(59). Whereas SS-R were located on tumor tissue, EGF-
R were often seen on adjacent normal lobules and ducts.
On the other hand, using a biochemical assay for EGF-
R, we did not observe a significant correlation between
EGF-R and SS-R (41). Also, Fekete et al. (42) found no
relationship between EGF-R and SS-R both measured
by Scatchard analysis.
11. Relationship with membrane-bound tissue plasmino-
gen activator. There is a large amount of evidence that
plasminogen activators (PA) are involved in tumor in-
vasion and metastasis. Harris and Nicholson (25) divided
43 breast cancers into ER+/EGF-R-, ER-/EGF-R+,
and ER-/EGF-R— subgroups. While there was no signif-
icant difference in total PA between these groups, tissue
PA (tPA) was significantly lower in ER-/EGF-R+ tu-
mors. The lack of PA appeared to be associated with an
aggressive group of tumors, and it was suggested that
EGF-R might have a role in suppressing tissue PA secre-
tion (25).
C. Relationship with prognosis and survival
1. Relationship with relapse-free (RFS) and overall sur-
vival (OS). Thus far nine different groups (20-21, 24, 30,
32, 35, 39, 41, 44, 67, 72-74) have reported on the
relationship between EGF-R and survival. The size of
the series of patients investigated ranged from 55-376
with EGF-R positivity in 14-55% (Table 6). The median
(12-66 months) and maximal (30-96 months) follow-up
showed great differences. In the majority of the studies
systemic adjuvant therapy was given in a number of
patients, mostly in the node-positive group. Using uni-
variate analysis, five groups (21, 24, 30, 32, 39, 67) found
a significant relationship between EGF-R status and
RFS or OS at a certain time point of follow-up (Table
6). This finding was confirmed in two of three studies
using multivariate analysis.
Sainsbury et al. (24) indicated that by multivariate
analysis EGF-R status was the most important variable
in predicting RFS and OS in lymph node-negative pa-
tients and the second most important variable in lymph
node-positive patients. RFS and OS were significantly
worse for patients with EGF-R-positive tumors as com-
pared to patients with EGF-R-negative tumors. The best
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discriminative effect was found in subgroups with lymph
node-negative or ER-negative tumors. In contrast, we
found only a tendency (P 0.09) for a negative relationship
between EGF-R and RFS (41). Macias et al. (20) initially
reported a 6-yr relapse rate in 10 of 20 (50%) patients
with EGF-R positive tumors vs. 22 of 52 (40%) patients
with EGF-R negative tumors, but this difference was not
statistically significant. They later observed a significant
relationship in a larger series of patients with shorter
follow-up interval (21). Grimaux et al. (39) reported a
nearly significant prognostic value (P 0.051) when over-
all survival curves were analyzed at 40 months follow-up
[which is comparable to the follow-up duration in the
study of Sainsbury (24)], but EGF-R failed to predict
long-term outcome. Spyratos et al. (35) also found that
EGF-R had no predictive value for long-term outcome.
Two other studies, by Costa et al. (32) and Lewis et al.
(67), reported a significant prognostic relationship, but
their patient follow-up period was very short. Toi et al.
(44) observed a relapse in 23% of EGF-R-positive pa-
tients and only 6% in EGF-R-negative patients, but the
statistical significance in this was not indicated.
Coombes et al. (74), measuring transcripts for EGF-R,
found no relationship with relapse-free survival.
In contrast to Sainsbury et al. (24) we found the best
discriminative effects of EGF-R to be in lymph node-
positive or ER-positive patient subsets (41). Lewis et al.
(67), in agreement with Sainsbury's results (24), found a
significant discriminative effect of EGF-R in the ER-
negative subgroup of patients, but the other groups of
investigators (20, 21, 32, 35, 39, 41) did not make such
an observation, although a tendency to such relationship
was present in two (32, 39) of these studies (Table 6).
Rios et al. (21) found only a significant discriminative
effect of EGF-R in ER-positive patients. EGF-R+/ER-
patients showed the poorest and EGF-R-/ER+ patients
the best survival probability (21, 39) due, no doubt, to
the better discriminative effect of EGF-R in ER+ pa-
tients (21). Lymph node status and steroid receptor
content appeared to be better prognosticators than EGF-
R (20, 41), but in a subgroup of 55 node-positive patients
Grimaux et al. (39) reported that EGF-R was the only
biological parameter to reach statistical significance in
predicting for early death. Macias et al. (20) also reported
that within node- positive patients, EGF-R had prognos-
tic value that was not present within the node-negative
patient subgroup. Furthermore, Spyratos et al. (35) and
Costa et al. (32) found no significant prognostic effect in
node-negative patients. However, when, in the former
study (35), patients receiving prior adjuvant therapy were
excluded, EGF-R appeared as the only significant prog-
nostic variable (P 0.05). For those studies (24, 30, 67) in
which systemic adjuvant therapy had not been given, the
best discriminative effect of EGF-R was observed.
In summary, five (21, 24, 32, 39, 67) of nine study
groups have shown significant prognostic value for EGF-
R and survival after short-term (1-4 yr) follow-up, while
three (20, 39,41) of five groups (20,35, 39,41, 74), having
a maximal follow-up interval of at least 6 yr, found only
a tendency (0.10 > P > 0.05) associating EGF-R with
survival. It appears that EGF-R-positive tumors are
more prone to first relapses at visceral sites (24, 28, 44,
54), while EGF-R-negative tumors more often recur in
the bone.
2. Relationship with response to endocrine and chemo-
therapy. Nicholson et al. (28,30) reported that expression
of EGF-R is associated with lack of response to endocrine
therapy in recurrent breast cancer. Only 8% of EGF-R-
positive tumors showed an objective response to first-
line treatment with tamoxifen in metastatic breast can-
cer while 30% of EGF-R-negative tumors responded (P
< 0.05). Only one of 28 EGF-R +/ER- tumors achieved
an objective response. Patients with EGF-R-positive pri-
mary tumors showed more rapid disease progression after
start of first-line endocrine therapy than those with
EGF-R-negative tumors. In one preliminary study, Har-
ris (29) observed that in 25 patients, who received first-
line single chemotherapy with mitoxantrone, there was
no correlation between EGF-R status and response to
therapy, time to tumor progression, or survival.
IV. Summary
EGF-R positivity was shown to be present in 2500
(48%) of 5232 breast tumors in 40 different series of
patients. The mean of the percentages of EGF-R positiv-
ity in the individual series reported by these 40 different
groups of investigators is 45% (range 14-91%). Overall
there are generally no clear differences between results
obtained by radioligand binding assays, immunological
methods, autoradiography, and measurement of EGF-R
transcripts although the mean percentage of EGF-R-
positive tumors determined by immunological methods
tends to be somewhat lower. Nearly all studies indicate
a negative relationship between EGF-R and steroid re-
ceptor status (28 of 31 studies for ER, 12/19 for PR)
showing that EGF-R positivity is twice as high in ER or
PR- negative tumors compared to ER or PR- positive
tumors (-50-60% vs. 30%). With regard to other prog-
nostic factors the majority of investigators (10/18) also
reported a significant (positive) correlation with tumor
grade, but only a minority found a significant relation-
ship between EGF-R status and patient age (2/9), men-
opausal status (1/7), histological type (3/7), tumor size
(2/17), nodal status (5-9/20), ploidy (1/7), or prolifera-
tion indices (3/9). No relationship was observed with
tumor insulin-like growth factor I receptor, PRL receptor
(PRL-R), and LHRH receptor (LHRH-R) status, but an
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inverse relationship between EGF-R and somatostatin
receptor may be present. However, it has to be stressed
that the series in which the relationship between EGF-
R status and other prognostic factors were investigated,
contained relatively few patients (mostly <100). There-
fore, when larger groups of patients are investigated,
more significant relationships may be observed, espe-
cially with respect to nodal status, tumor ploidy, and
proliferation indices. In fact, we calculated the presence
of EGF-R positivity overall in 35% of 253 aneuploid
tumors vs. in only 15% of 114 diploid tumors (P <
0.0001). In addition most studies observed a trend, if no
significant correlation, between higher EGF-R levels in
tumors with the highest percentages of S-phase or Ki-67
expression. With regard to relapse-free and overall sur-
vival, five of nine different groups of investigators
showed significant prognostic value of EGF-R after
short-term (1- to 4-yr) follow-up, indicating that patients
with EGF-R-positive tumors have a poor prognosis.
However, three of five groups with a maximal follow-up
of at least 6 yr found only a tendency for any relationship
between EGF-R status and long-term outcome.
V. Discussion and Conclusions
The efficacy and cost effectiveness of adjuvant sys-
temic therapy in women with primary breast cancer are
important subjects of current debate (85, 86). More se-
lective use of chemotherapy to maximize the benefit to
individual patients may be possible with refinements in
risk stratification and better assessment of the patients'
risk preferences. There are numerous prognostic factors
reported for primary breast cancer (see review in Ref.
87). EGF-R is a more recent tumor marker whose prog-
nostic value has been well studied but remains contro-
versial. This may be due to differences in techniques
used for EGF-R measurements or cut-off levels chosen
for EGF-R positivity. However, we could find no clear
differences between the results obtained by radioligand
binding assay, immunological methods, autoradiography,
or measurement of EGF-R transcripts. The slighty lower
EGF-R positivity using immunological methods might
by explained by a lower assay sensitivity than for ligand
binding assays, accounting for EGF-R-positive tumors
by ligand binding assay that are negative by immunohis-
tochemical analysis (25). In some cases EGF-R was
undetectable by ligand binding or immunochemistry but
could be detected by enhancement of autophosphoryla-
tion with EGF (25).
Despite the great variation in cut-off levels for EGF-
R positivity, nearly all investigators report a negative
relationship between tumor EGF-R status and steroid
receptor levels. Although ER levels are positively corre-
lated with age (87, 88), there is an absence of such a
relation between EGF-R and age or menopausal status,
as observed by nearly all investigators. We also found a
negative relationship between cytosolic EGF/TGF-a-like
activities [growth factors that can influence the number
of detectable EGF-R (89, 90)] and steroid receptor levels
in breast cancer (40). Macias et al. (91) showed higher
TGF« contents in metastatic than in primary breast
cancer, but, in contrast to our findings, did not find a
correlation between tumor TGFa content and ER levels.
Measuring gene transcripts of EGF, ER, and PR, Dot-
zlaw et al. (92) recently showed that EGF was more
frequently detectable in ER or PR-positive tumors than
in ER or PR-negative breast tumors. They also demon-
strated a positive association between EGF messenger
RNA and steroid receptor levels. However, Barrett-Lee
et al. (72) and Coombes and co-workers (73, 74) observed
no association between TGFa mRNA and survival.
The results correlating EGF-R status and RFS are
very controversial: some groups have found a very close
correlation, while others have found only a tendency or
no significant relationship between these parameters.
Comparing EGF-R status with previously validated prog-
nostic indices, Hainsworth et al. (70) observed a signifi-
cant association, but Lewis et al. (67) did not. Sainsbury
et al. (24) found by multivariate analysis that EGF-R
status was the most important variable in predicting
RFS and OS in lymph node-negative patients and the
second most important variable in lymph node-positive
patients. Spyratos et al. (35) noted that although EGF-
R status had overall no significant prognostic value, it
was the only significant prognosticator in node-negative
patients, while Lewis et al. (67) stated that EGF-R was
the third most important prognosticator after nodal sta-
tus and grade. However, with respect to subgroup analy-
sis by nodal or ER status, there is no agreement on the
best prognosticator and in which subgroup EGF-R status
offers the most predictive power. The differences in
results and conclusions might partly be due to differences
in patient number, cut-off levels for both EGF-R and
ER, application of systemic adjuvant therapy, and du-
ration of patient follow-up—generally concerns affecting
the evaluation of other prognostic factors (15). In view
of the prominent predictability value of EGF-R status in
those series in which patients were not treated with
adjuvant therapy, and the observed association between
tumor EGF-R positivity and lack of response to endo-
crine therapy (but not to chemotherapy) in patients with
metastatic disease, the overall influence of adjuvant sys-
temic treatment on the prognostic power of EGF-R sta-
tus has yet to be established (especially for long-term
outcome).
Furthermore, it has to be stressed that the size of all
reported series are generally small, ranging from 20 or
30 to a few hundred patients. Only three studies (30, 32,
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41) included more than 200 patients. Furthermore, apart
from assessment by P values in univariate and multivar-
iate analysis in relation to RFS and OS, the potential
impact of a prognostic factor should preferably also be
expressed by positive and negative predictive values and
their differences. For example Nicholson et al. (30) report
a 5 yr RFS of approximately 20% (derived from the
figure) for patients with EGF-R+ tumors (positive pre-
dictive value at 5 yr) and a 5 yr RFS of 38% for patients
with EGF-R-tumors (negative predictive value at 5 yr of
follow-up). The difference of these values (18%) is a
measure of the impact of the prognostic value of EGF-
R. Similarly, Foekens et al (41) have shown a 5 yr RFS
of approximately 43% and 67% for patients with low or
high and intermediate EGF-R tumor values, respectively,
thus a difference of 24%. Unfortunately, in the other
studies indicated in Table 6, it appears difficult to eval-
uate the prognostic value of EGF-R other than in terms
of significant P values. Therefore, to make definite con-
clusions about the relationships and predictive value of
EGF-R status, larger confirmatory studies with long-
term follow-up periods are warranted.
It would also be essential to have a standardized EGF-
R assay. In view of the lack of a uniform method for
EGF-R measurement and uniform criterion for positivity
(cut-off point), the authors propose standardization of
EGF-R assays. In this respect it is noteworthy to mention
that the EORTC Receptor Study Group has recently
declared the hydroxylapatite method as the method of
choice to separate bound from free ligand (93). After
minor modification, this HAP-assay adopts a membrane
protein threshold of 0.2 mg/ml in order to avoid false-
negative results due to too low protein content (53). A
clinically valuable significant cut-off level for positivity
of EGF-R using this assay has yet to be determined by
taking length of RFS and OS as endpoints. For smaller
tissue samples or cytological samples, autoradiography
or immunoassays may be used. Apart from the consensus
reached by the EORTC Receptor Study Group to use
HAP adsorption of EGF-R as a tool to separate bound
from free ligand by low-speed centrifugation procedures,
more work has to be done before the EGF-R assay will
be completely standardized. Major aspects that need
standardization include the membrane preparation to be
used and the reference parameter on which to express
EGF-R {e.g. protein, DNA, wet weight, or a membrane
marker such as 5'-nucleotidase).
In view of the close similarity between EGF-R (c-
erbB-1) and HER2/new (c-erbB-2) oncogene protein, it
is interesting to compare the clinical relationships and
prognostic value of these two membrane markers. For
the EGF-R gene a great difference has been found be-
tween the incidence of gene amplification (0-14%) (71,
76, 77) relative to protein (over)expression (about half
of the patients), in contrast to HER2/rceu in which there
is a strong correlation between amplification and over-
expression. Amplification and/or overexpression of the
HER2/rceu gene has been described in approximately
20% of breast tumors (range 8-64%) (94-100). In our
most recent update (100) of the literature, data encom-
passing a total of 11,408 breast tumors, we calculated a
mean HER2/new positive incidence of 20% without find-
ing any significant difference between the incidence of
amplification and overexpression. This means that EGF-
R-positive tumors relate to a greater proportion (45%)
of breast cancer patients than do HER2/neu positive
tumors (20%), which might suggest an advantage for the
measurement of EGF-R as prognostic parameter. The
prognostic value of HER2/nea amplification in breast
cancer has been studied extensively since the initial
report by Slamon et al. (101), showing that HER2/neu
amplification is an independent prognostic factor in
node-positive patients. Recent reviews (94-99) suggest
that there is no association between elevated HER2/neu
and patient age, only a tentative relationship with tumor
grade, size, or nodal involvement, and an inverse asso-
ciation with steroid hormone receptors. There is no
consensus on the independent prognostic power of
HER2/rcew to predict either RFS or OS. Most interest-
ingly, these relationships and conclusions are similar and
comparable to those described for EGF-R in this review.
Few authors (70,82) have compared the prognostic power
of EGF-R and HER2/new in the same study, and these
show conflicting results (see Section B.9).
Conclusions
Based on 40 separate studies comprising 5232 patients,
the mean percentage of EGF-R positivity reported in
breast cancer is 45% (range 14-91%).
Overall, there is no clear difference in results between
radioligand binding assays, immunological methods, au-
toradiography, and measurement of EGF-R transcripts
(mean EGF-R positivity for respective techniques rang-
ing between 42-48%), although EGF-R positivity by
immunological methods tends to be lower.
In view of the lack of an uniform method for EGF-R
measurement and uniform criterion for positivity (cut-
off point), the authors propose standardization of EGF-
R assays as established by the EORTC in order to employ
such standard methods for clinical trials involving EGF-
R.
Correlations with other prognostic factors and with
prognosis in lymph node-negative and positive disease
can be made based on the current literature but will
likely be more clear if such standard methodology is
accepted, as occurred for ER and PR.
There is a negative correlation between EGF-R and
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steroid receptor (ER, PR) levels showing that EGF-R-
positivity is twice as high in ER- or PR-negative tumors
than in ER- or PR-positive tumors (-50-60% vs. 30%).
There is no relationship between EGF-R status and
age or menopausal status.
There is no clear association between EGF-R and
tumor size.
Some authors suggest that there is a higher incidence
of EGF-R positivity for primary tumors in patients with
nodal involvement or higher EGF-R levels in lymph node
metastases/recurrences as compared to primary tumors,
but other studies disagree.
There may be higher EGF-R positivity in ductal car-
cinomas than in lobular carcinomas, but this is not a
uniform observation.
There is a likely association between high EGF-R
levels and poor tumor differentiation and grade.
When the results of several studies are combined there
appears to be an association between a higher (2- to 3-
fold) incidence of EGF-R positivity and aneuploid tu-
mors as compared to diploid tumors.
A few studies indicate a positive correlation between
EGF-R and higher rates of breast cancer proliferation.
There is no relationship between EGF-R and IGF-1-
R, PRL-R, or LHRH-R, but possibly an inverse relation-
ship with SS-R.
There is little agreement on the prognostic value of
EGF-R, with most studies indicating a tendency or weak
association between EGF-R and RFS or OS. There is
also no agreement on the subgroups of patients in which
EGF-R may have a discriminative prognostic effect. The
discriminatory effect of EGF-R status with respect to
prognosis seems to decrease with long-term follow-up
compared to short follow-up as previously shown and
discussed by some authors (88, 102) for the ER status.
Patients with advanced disease and EGF-R-positive
tumors respond less well to first-line endocrine treatment
as compared to EGF-R-negative tumors, but the signifi-
cance of this independence of ER status is unknown.
There is no apparent relationship between EGF-R status
and response to first-line chemotherapy, but this has not
been well studied.
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